Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Ashwini Vishweswaramurthy"'
Autor:
Mark A. Socinski, Cornelius F. Waller, Tazeen Idris, Igor Bondarenko, Alexander Luft, Katrin Beckmann, Ashwini Vishweswaramurthy, Subramanian Loganathan, Charles Donnelly, Matthew A. Hummel, Roxann Shapiro, Melody Woods, Anita Rao, Vivek G Nayak, Gopinath Ranganna, Abhijit Barve
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Purpose: This phase III study compared the efficacy and safety of proposed biosimilar MYL-1402O with reference bevacizumab (BEV), as first-line treatment for patients with stage IV non-squamous non-small-cell lung cancer. Patients and methods: Patien
Externí odkaz:
https://doaj.org/article/c16131d828264fbc8bb2cf1ee253522f
Autor:
Anand Khedkar, Harold Lebovitz, Alexander Fleming, Alan Cherrington, Vinu Jose, Sandeep N. Athalye, Ashwini Vishweswaramurthy
Publikováno v:
Clinical and Translational Science, Vol 12, Iss 3, Pp 276-282 (2019)
Oral insulin tregopil (IN‐105; a new drug under development) may be coadministered with oral antidiabetic drugs, such as metformin in patients with type 2 diabetes mellitus for optimal glycemic control. IN‐105 has sodium caprate excipient, a perm
Externí odkaz:
https://doaj.org/article/5384bf85ebe146518da77ac1c6056bdf
Autor:
Harold E Lebovitz, Alexander Fleming, Alan D Cherrington, Shashank Joshi, Sandeep N Athalye, Subramanian Loganathan, Ashwini Vishweswaramurthy, Jayanti Panda, Ashwani Marwah
Publikováno v:
Expert opinion on pharmacotherapy. 23(16)
Efficacy and safety of ultra-rapid acting oral prandial insulin Tregopil was compared with insulin aspart (IAsp) in patients with type 2 diabetes (T2D) on insulin glargine and metformin. In this open-label, active-controlled trial, patients with T2D,
Autor:
Harold E Lebovitz, Alexander Fleming, Alan D Cherrington, Shashank Joshi, Sandeep N. Athalye, Subramanian Loganathan, Ashwini Vishweswaramurthy, Jayanti Panda, Ashwani Marwah
OBJECTIVEEfficacy and safety of ultra-rapid acting oral prandial insulin Tregopil (Tregopil) was compared with insulin aspart (IAsp) in patients with type-2 diabetes on stable doses of insulin glargine and metformin.RESEARCH DESIGN AND METHODSIn this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10b9f83d3ed30de27df9bc02c2088e0b
https://doi.org/10.1101/2022.02.15.22270708
https://doi.org/10.1101/2022.02.15.22270708
Autor:
Sandeep N. Athalye, Harold E. Lebovitz, Ashwini Vishweswaramurthy, Anand Khedkar, Alexander Fleming, Vinu Jose, Alan D. Cherrington
Publikováno v:
Clinical Pharmacology in Drug Development
We evaluated the pharmacokinetics and pharmacodynamics of oral insulin tregopil in relation to premeal dosing time, between‐meal interval, and meal composition type in type 2 diabetes mellitus patients in a randomized, placebo‐controlled, crossov
Autor:
Ashwini Vishweswaramurthy, Harold E. Lebovitz, Alexander Fleming, Alan D. Cherrington, Vinu Jose, Sandeep N. Athalye, Anand Khedkar
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 12, Iss 3, Pp 276-282 (2019)
Clinical and Translational Science, Vol 12, Iss 3, Pp 276-282 (2019)
Oral insulin tregopil (IN-105; a new drug under development) may be coadministered with oral antidiabetic drugs, such as metformin in patients with type 2 diabetes mellitus for optimal glycemic control. IN-105 has sodium caprate excipient, a permeati
Autor:
Mark A. Socinski, Matthew A. Hummel, Cornelius F. Waller, Russell J. Rackley, Tazeen Idris, Joel Owen, Sundara Moorthi Nainar Murugesan, Gopinath Ranganna, Mark Liu, Stefan Roepcke, Ashwini Vishweswaramurthy, Hannah Huang, Abhijit Barve, Subramanian Loganathan
Publikováno v:
Journal of Clinical Oncology. 39:e21087-e21087
e21087 Background: MYL-1402O (MYL) is a proposed biosimilar to bevacizumab reference product. A multicenter, double blind randomized, phase 3 study compared the efficacy, safety, PK, and immunogenicity of MYL and Avastin in patients with Stage IV met
Autor:
Cornelius F. Waller, I. Bondarenko, Ashwini Vishweswaramurthy, G. Ranganna, Mark A. Socinski, T. Idris, Alexander Luft, K. Beckmann, Abhijit Barve, Subramanian Loganathan
Publikováno v:
Annals of Oncology. 31:S883-S884
Autor:
Cornelius F. Waller, Mark A. Socinski, Igor Bondarenko, Vivek G Nayak, Melody Woods, Matthew A. Hummel, Ashwini Vishweswaramurthy, Gopinath Ranganna, Roxann Shapiro, Katrin Beckmann, Subramanian Loganathan, Tazeen Idris, Anita Rao, Alexander Luft, Abhijit Barve, Charles Donnelly
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Purpose: This phase III study compared the efficacy and safety of proposed biosimilar MYL-1402O with reference bevacizumab (BEV), as first-line treatment for patients with stage IV non-squamous non-small-cell lung cancer. Patients and methods: Patien
Autor:
Ashwini Vishweswaramurthy, Harold E. Lebovitz, Anand Khedkar, Vinu Jose, Sandeep N. Athalye, Alan D. Cherrington, Gilbert Alexander Fleming
Publikováno v:
Diabetes. 67
Our aim was to evaluate pharmacodynamics (PD) of insulin tregopil (IN-105) in relation to meal composition in type 2 diabetes mellitus patients in placebo-controlled, crossover study. Eighteen patients were randomised to 6 sequences and administered